Policy brief: off-label medicines: rational or irrational?

07 September 2017

Based on mounting evidence on the potential for significant cost-savings in the use of off-label medicines, there is a need for the Ministry of Health in Indonesia to consider their use under the national health insurance benefits package. This policy brief details the findings of a study which reviewed the laws, regulations and practices related to the use of off-label medicines in a number of developed and developing countries, as part of a rational and evidence-informed approach to decision-making.

Document group
Briefs
Download link
Share on